Different glaucoma progression rates by age groups in young myopic glaucoma patients.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Optic Disk* ; Glaucoma* ; Low Tension Glaucoma* ; Myopia*; Humans ; Young Adult ; Adult ; Middle Aged ; Retrospective Studies ; Visual Fields ; Intraocular Pressure ; Nerve Fibers ; Disease Progression ; Tomography, Optical Coherence

We aimed to investigate the age-related glaucoma progression rates in myopic normal tension glaucoma (NTG). In this long-term retrospective cohort (7.2 ± 3.5 years), we grouped patients based on their age at initial presentation: group A (age < 30 years, 60 eyes), group B (30 ≤ age < 40, 66 eyes), and group C (40 ≤ age < 50 years, 63 eyes). We used a linear mixed-effects model to estimate retinal nerve fiber layer (RNFL) defect width enlargement rates. Group A showed a significantly faster rate of RNFL defect progression (3.01 ± 1.74°/year) than those of groups B and C (2.05 ± 1.55°/year and 2.06 ± 1.29°/year, P = 0.004 and 0.002). The difference was more marked when calculated for the first 10 years of follow-up in group A, B, and C (3.95 ± 2.70°/year, 2.39 ± 1.64°/year, and 1.98 ± 1.31°/year), and between the periods of age < 30 years, 30 ≤ age < 40 years, and 40 ≤ age < 50 years within group A. This is the first evidence of rapid glaucoma progression in the young adulthood and stabilization in older age in myopic NTG. Clinicians should consider the potentially aggressive course of glaucoma, especially in younger patients with myopic NTG, in contrast to the general slow progression in adulthood.
(© 2024. The Author(s).)

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1635-41. (PMID: 17389494)
BMC Ophthalmol. 2020 Apr 9;20(1):141. (PMID: 32272929)
Am J Ophthalmol. 2002 Feb;133(2):187-95. (PMID: 11812421)
Ophthalmology. 2000 Sep;107(9):1688-92. (PMID: 10964831)
Ophthalmology. 2013 Jul;120(7):1380-7. (PMID: 23541761)
Acta Ophthalmol Scand. 2000 Feb;78(1):49-52. (PMID: 10726789)
Am J Ophthalmol. 2019 Jul;203:89-102. (PMID: 30825418)
Curr Eye Res. 2014 Nov;39(11):1099-105. (PMID: 24749850)
Ophthalmology. 2007 Mar;114(3):472-9. (PMID: 17123617)
Eye (Lond). 2010 May;24(5):857-63. (PMID: 19680281)
Am J Ophthalmol. 2022 Apr;236:107-119. (PMID: 34648776)
Br J Ophthalmol. 2023 May;107(5):644-649. (PMID: 34937695)
Am J Ophthalmol. 2020 Jan;209:77-87. (PMID: 31493404)
Invest Ophthalmol Vis Sci. 2012 Jul 03;53(8):4485-9. (PMID: 22695960)
Ophthalmology. 2011 Oct;118(10):1989-1994.e2. (PMID: 21684603)
Arch Ophthalmol. 1995 May;113(5):586-96. (PMID: 7748128)
Lancet. 2017 Nov 11;390(10108):2183-2193. (PMID: 28577860)
Br J Ophthalmol. 2023 Jun;107(6):869-875. (PMID: 35017160)
Ophthalmology. 2016 May;123(5):1036-42. (PMID: 26875007)
Ophthalmology. 2012 Sep;119(9):1844-51. (PMID: 22595297)
Eye Contact Lens. 2018 Jul;44(4):248-259. (PMID: 29923883)
Br J Ophthalmol. 2009 Sep;93(9):1141-2, 1185. (PMID: 19704038)
J Glaucoma. 2015 Jun-Jul;24(5):335-43. (PMID: 23970341)
Ophthalmology. 2022 Mar;129(3):333. (PMID: 35190098)
Ophthalmology. 2014 May;121(5):1013-9. (PMID: 24507857)
Am J Ophthalmol. 2016 Sep;169:33-45. (PMID: 27318077)
J Glaucoma. 2018 Mar;27(3):269-274. (PMID: 29303874)
Invest Ophthalmol Vis Sci. 2023 Aug 1;64(11):12. (PMID: 37552032)
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6208-16. (PMID: 26426403)

Date Created: 20240131 Date Completed: 20240202 Latest Revision: 20241023

20241023

PMC10830449

10.1038/s41598-024-53133-w

38297037